The IL-6/STAT3 pathway is hyperactivated in many types of cancers, and treatments that target the IL-6/STAT3 pathway have been widely studied and are listed as follows: directly targeting IL-6 with antibodies, such as siltuximab; targeting IL-6R with antibodies, such as tocilizumab; and targeting STAT3 inhibitors, such as peptidomimetics37. The gene discussed is STAT3; the disease is cancer.